Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 260-892-4 | CAS number: 57674-14-3
Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Reliability:
- 4 (not assignable)
- Rationale for reliability incl. deficiencies:
- documentation insufficient for assessment
Data source
Reference
- Reference Type:
- other company data
- Title:
- Unnamed
- Year:
- 1 975
- Report date:
- 1976
Materials and methods
- Principles of method if other than guideline:
- The sample was applied to rats in CMC aqueous solution. After substance administration, the symptoms were observed for 14 days.
- GLP compliance:
- no
- Remarks:
- pre GLP
- Test type:
- standard acute method
Test material
- Reference substance name:
- Trisodium bis[3-[(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)azo]-4-hydroxy-5-nitrobenzenesulphonato(3-)]chromate(3-)
- EC Number:
- 260-892-4
- EC Name:
- Trisodium bis[3-[(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)azo]-4-hydroxy-5-nitrobenzenesulphonato(3-)]chromate(3-)
- Cas Number:
- 57674-14-3
- Molecular formula:
- C32H20CrN10O14S2.3Na
- IUPAC Name:
- trisodium bis[3-[(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)azo]-4-hydroxy-5-nitrobenzenesulphonato(3-)]chromate(3-)
Constituent 1
Test animals
- Species:
- rat
Administration / exposure
- Route of administration:
- oral: unspecified
- Vehicle:
- CMC (carboxymethyl cellulose)
- Details on oral exposure:
- Aqueous suspension of 0.5 % CMC
- Details on study design:
- - Duration of observation period following administration: 14 days.
- Necropsy of survivors performed: yes
Results and discussion
Effect levels
- Dose descriptor:
- LD50
- Effect level:
- 7 000 other: mg/kg
- Based on:
- test mat.
- Clinical signs:
- Dyspnoea, apathy, prone position, systemic skin discoloration, urine and feces red coloured, dehydration, poor general condition, initially slight weight loss.
- Gross pathology:
- Acute cardiac dilatation both sides, acute hyperaemia, mucosa in the glandular stomach astringent, fatty tissue dyed.
Applicant's summary and conclusion
- Interpretation of results:
- other: Not classified according to the CLP Regulation
- Conclusions:
- LD50 oral was stated at 7000 mg/kg
- Executive summary:
- Method
The sample was applied to rats in CMC aqueous solution. After substance administration, the symptoms were observed for 14 days.
Results
LD50 oral was stated at 7000 mg/kg.
Dyspnoea, apathy, prone position, systemic skin discoloration, urine and feces red coloured, dehydration, poor general condition, initially slight weight loss were observed. Furthermore, the gross analyses revealed acute cardiac dilatation both sides, acute hyperaemia, mucosa in the glandular stomach astringent, fatty tissue dyed.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
